Abstract
Requirement of methotrexate in combination with anti-tumor necrosis factor-alpha therapy for adequate suppression of osteoclastogenesis in rheumatoid arthritis.
Hiroaki Matsuno, Kaoru Yoshida, Akira Ochiai and Masahiro Okamoto
The Journal of Rheumatology December 2007, 34 (12) 2326-2333;
Hiroaki Matsuno
Kaoru Yoshida
Akira Ochiai
In this issue
The Journal of Rheumatology
Vol. 34, Issue 12
1 Dec 2007
Requirement of methotrexate in combination with anti-tumor necrosis factor-alpha therapy for adequate suppression of osteoclastogenesis in rheumatoid arthritis.
Hiroaki Matsuno, Kaoru Yoshida, Akira Ochiai, Masahiro Okamoto
The Journal of Rheumatology Dec 2007, 34 (12) 2326-2333;